C-Reactive Protein Testing Market To Reach $6.08 Billion By 2033

January 2026 | Report Format: Electronic (PDF)

C-Reactive Protein Testing Market Growth & Trends

The global C-reactive protein testing market size is expected to reach USD 6.08 billion by 2033, registering a CAGR of 1.68% from 2026 to 2033, according to a new report by Grand View Research, Inc. The growth of C-reactive protein (CRP) testing can be attributed to significant research activities aimed at exploring various applications of testing. These research efforts are further facilitated by the presence of both private and public agencies that provide funding to expedite research in this field. The market is anticipated to witness significant growth owing to advancements in nanotechnological tools. These advancements offer promising opportunities to develop portable bioanalytical assays that possess attributes, such as high specificity, sensitivity, rapid response time, and the ability to perform multiplexing for accurate disease diagnosis and monitoring at the point of care.

These advancements are expected to drive the demand for CRP testing during the forecast period. Furthermore, an increase in strategic deals and developments, as well as higher investments in research and development has fueled the growth. The COVID-19 pandemic has had a considerable impact on the market, as CRP is considered a crucial biomarker for assessing the severity of infection and inflammation. As a result, there is an increased demand for services and products. Leading companies, such as Abbott, provide supportive tools for CRP testing specifically for SARS-CoV-2 infection, further contributing to market growth. Moreover, key players increased focus on product launches and developments in point-of-care CRP tests, which is projected to further fuel the market's growth in the coming years.

For instance, in July 2022, Bloom Diagnostics introduced the Bloom Inflammation Test, a semi-automated testing kit designed for the quantification of CRP levels in the blood. This single-use kit aids in the detection of inflammation within the body. The growth of the marketplace is expected to be further stimulated by the establishment of testing facilities. In June 2021, Trivitron Healthcare unveiled a mobile laboratory for COVID-19 diagnostics, enabling testing services in various regions of India, including rural, urban, and remote areas. This indigenous laboratory offers a range of tests, including CLIA/Elisa tests for inflammatory markers, such as a CRP, IL-6, and D-Dimer, as well as rapid antigen tests, RT-PCR tests, CLIA/Elisa Antibodies Tests IgM and IgG, and others.

North America held the largest revenue share of 39.42% in 2022 and is expected to maintain its share during the forecast period due to the increasing prevalence of cardiovascular diseases, a steady stream of product launches, presence of established market players, technological advancements, and well-developed healthcare infrastructure. Asia Pacific is projected to grow at the fastest CAGR of 0.49% from 2023 to 2030. The COVID-19 pandemic originated in China. Being the potential biomarker for determining the severity of the infection, the demand for CRP testing is expected to increase shortly. Key players operating in the global industry are constantly focusing on product launches and geographical expansion to maintain their presence.

key Request a free sample copy or view report summary: C-reactive Protein Testing Market Report

C-Reactive Protein Testing Market Report Highlights

Based on assay type, the immunoturbidimetric assay segment dominated the global market and accounted for the largest revenue share of 48.46% in 2025. ELISA held the second-largest market share in 2025.
Based on detection range, the hs-CRP segment held the largest revenue share of 62.02% in 2025. The conventional CRP segment is expected to grow at a substantial rate over the forecast period.
Based on disease area, the rheumatoid arthritis segment held the largest revenue share of 25.78% in 2025. Cardiovascular diseases are projected to grow significantly during the forecast period.
Based on end-use, the hospitals dominated the market with a revenue share of 38.17% in 2025. Laboratories are expected to grow at a substantial rate over the forecast period.
North America c-reactive protein testing market dominated the global market and accounted for the largest revenue share of 40.86% in 2025.

C-Reactive Protein Testing Market Segmentation

Grand View Research has segmented global C-reactive protein testing market report based on assay type, detection range, disease area, end-use, and region:

C-Reactive Protein Testing Assay Type Outlook (Revenue, USD Million, 2021 - 2033)

Immunoturbidimetric Assay
ELISA
- Clinical
- Nonclinical
Chemiluminescence Immunoassay
Others

C-Reactive Protein Testing Detection Range Outlook (Revenue, USD Million, 2021 - 2033)

hs-CRP
Conventional CRP
cCRP

C-Reactive Protein Testing Disease Area Outlook (Revenue, USD Million, 2021 - 2033)

Cardiovascular Diseases
Cancer
Rheumatoid Arthritis
Inflammatory Bowel Disease
Endometriosis
Lupus
Others

C-Reactive Protein Testing End-use Outlook (Revenue, USD Million, 2021 - 2033)

Clinics
- By Entity
  - Physician Offices
  - Small Clinics
  - Others
- By Settings
  - Urban Setting
  - Rural Setting
Hospitals
- Urban Setting
- Rural Setting
Laboratories
- Urban Setting
- Rural Setting
Assisted Living Healthcare Facilities
- Urban Setting
- Rural Setting
Home
Others